Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

China flag China · Delayed Price · Currency is CNY
6.17
-0.11 (-1.75%)
May 20, 2026, 1:45 PM CST
Market Cap6.45B -1.7%
Revenue (ttm)591.59M +1.3%
Net Income-479.28M
EPS-0.48
Shares Out1.03B
PE Ration/a
Forward PEn/a
Dividend0.01 (0.15%)
Ex-Dividend DateJul 4, 2025
Volume17,437,909
Average Volume52,511,905
Open6.14
Previous Close6.28
Day's Range6.12 - 6.27
52-Week Range5.47 - 9.40
Beta0.10
RSI38.68
Earnings DateApr 29, 2026

About Beijing SL Pharmaceutical

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase... [Read more]

Sector Healthcare
Founded 1994
Employees 901
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002038
Full Company Profile

Financial Performance

In 2025, Beijing SL Pharmaceutical's revenue was 623.64 million, a decrease of -5.57% compared to the previous year's 660.42 million. Losses were -347.20 million, 368.8% more than in 2024.

Financial Statements